检索结果-南通市图书馆

Journal of Clinical and Nursing Research 2024年第5期8卷 124-128页

作者： Lin Ma Zhangjiakou First Hospital Zhangjiakou 075000Hebei ProvinceChina

Prostate cancer is a malignant tumor with a high incidence in elderly *** recent years,with the improvement of people’s living standards and the advancement of detection technology,the incidence of prostate cancer has been increasing year by ***-resistant prostate cancer(CRPC)is a highly challenging type of advanced prostate cancer treatment,which clinically shows resistance to hormonal deprivation *** overall treatment efficacy of CRPC is currently poor and further relevant therapeutic studies are needed to improve patient survival and quality of *** can play a role in combating the immune system of tumors,and abiraterone has also achieved remarkable results in prostate cancer *** study will investigate the possible clinical effects and safety of immunosuppressants combined with abiraterone in the treatment of metastatic *** population-based study will provide clinicians with more effective treatment options,as well as enhance the understanding of novel combination therapy strategies to be implemented in the future for such patients.

关键词： Immunosuppressants abiraterone Prostate cancer Immune system

abiraterone acetate for prostate cancer： a new era ot hormonal therapies

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Andrology 2011年第5期13卷 663-664页

作者： Emmanuel S Antonarakis Johns Hopkins Sidney Kimmel Comprehensive CancerCenter Baltimore MD 21231 USA

Therapies targeting the androgen receptor （AR） axis have constituted the HolyGraft in the management of advanced prostate cancer for seven decades） These hormonal therapies have traditionally taken two main forms： those that suppress gonadal androgen synthesis （e.g., the gonadotropin releasing hormone agonists/antagonists, such as leuprolide）, and those that inhibit the AR directly （e.g., the anti-androgens, such as bicalutamide）. However, although the vast majority of patients with prostate cancer initiaUy respond favorably to androgen-ablative therapies （manifested by tumor regressions and symptomatic improvements）, all patients will eventually develop further disease progression after a median of 18-24 months. This transformed disease state, known as castration-resistant prostate cancer （CRPC）, is invariably fatal.

关键词： abiraterone hormonal therapies

Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer： a real-world retrospective study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Andrology 2018年第6期20卷 545-550页

作者： Jin-G Zhao Jian-Dong Liu Peng-Fei Shen Xin Tang Guang-Xi Sun Xing-Ming Zhang Jun-Ru Chen Kun-Peng Shu Ming Shi Hao Zeng Department of Urology Institute of Urology West China Hospital Sichuan University Chengdu 610041 China Department of Oncology West China Hospital Sichuan University Chengdu 610041 China

Even in the era of novel targeted agents, switching to a second-line nonsteroidal antiandrogen （NSAA） is still widely used in treating metastatic castration-resistant prostate cancer （mCRPC）, especially in undeveloped countries. However, whether prior treatment with a second-line NSAA would impact the efficacy of abiraterone acetate （Abi） remains uncertain, in the current study, 87 mCRPC patients treated with Abi were analyzed. Among them, 21 were treated with a second-line NSAA （from bicalutamide to flutamide） before receiving abiraterone, while the remaining 66 received Abi directly. Therapeutic efficacy of Abi was compared between those with and without prior second-line NSAA using Kaplan-Meier curves, log-rank test, and Cox regression models. The therapeutic efficacy of Abi was similar between those with or without the prior switching treatment of flutamide, in terms of either prostate-specific antigen progression-free survival （PSA-PFS, 5.5 vs 5.6 months, P = 0.967）, radiographic progression-free survival （rPFS, 12.8 vs 13.4 months, P = 0.508）, overall survival （OS, not reached vs 30.6 months, P = 0.606）, or PSA-response rate （71.4% [15121] vs 60.6% [40166], P = 0.370）. This is the first time that the impact of prior switching of treatment to a second-line NSAA on the efficacy of Abi in mCRPC patients has been addressed. Our data support that, use of prior sequential bicalutamide and flutamide does not seem to preclude response to abiraterone, although larger cohort studies and, ideally, a randomized controlled trial are needed. These findings will facilitate doctors＇ decision-making in the treatment of mCRPC patients, especially for those with previous experience of switching NSAA second-line treatments in the clinic.

关键词： abiraterone antiandrogen castration-resistant prostate cancer flutamide

Clinical activity of abiraterone plus prednisone in docetaxel-naive and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Andrology 2019年第2期21卷 131-136页

作者： Guo-Wen Lin Gao-Xiang Li Bo Dai Ding-Wei Ye Yun-Yi Kong Yue Wang Yi-Jun Shen Department of Urology Fudan University Shanghai Cancer CenterShanghai 20032China Department of Oncology Fudan University Shanghai Medical CollegeShanghai 200032China Department of Pathology Fudan University Shanghai Cancer CenterShanghai 200032China

This study investigated the clinical activity of abiraterone plus prednisone in docetaxel-naive and docetaxel-resistant Chinese patients with metastatic castratio n-resista nt prostate can cer(mCRPC).A total of 146 patie nts with docetaxel-naive group(103 cases)and docetaxel-resista nt group(43 cases)were en rolled from the Sha nghai Cancer Center(Sha nghai,Chin a)in this retrospective cohort *** efficacy endpoints were prostate-specific antigen response rate,prostate-specific antigen progress!on-free survival,clinical/radiographic progression-free survival,and overall survival in response to abiraterone plus *** higher prostate-specific antigen response rate was found in docetaxel-naive group(54.4%,56/103)compared to docetaxel-resistant group(34.9%,15/43)(P=0.047).In addition,significantly higher median prostate-specific antigen progress!on-free survival(14.0 vs 7.7 months,P=0.005),clinical or radiographic progression-free survival(17.0 vs 12.5 months,P=0.003),and overall survival(27.0 vs 18.0 mon ths,P=0.016)were found in docetaxel-naTve group compared to docetaxel-resistant group,*** univariate and multivariate analyses indicated that lower albumin and visceral metastases were independent significant predictors for shorter overall *** sum up,our data suggested that abiraterone plus prednisone was efficient in both docetaxel-naTve and docetaxel-resistant Chinese ***,higher PSA response rate and longer overall survival were observed in the docetaxel-naTve group,which suggested that abiraterone was more effective for docetaxel-naive patients than for docetaxel failures.

关键词： abiraterone acetate castration-resistant prostate cancer clinical activity docetaxel-naive docetaxel-pretreated

Response of prostate cancer to addition of dutasteride after progression on abiraterone

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Andrology 2021年第2期23卷 222-223页

作者： Jian-Po Lian Yuan-Yuan Gao Jing-Jie Tang Xi Chen Ying Liu Deng-Long Wu Zhen-Fei Li Sheng-Song Huang Department of Urology Tongji HospitalTongji University School of MedicineShanghai 200065China State Key Laboratory of Cell Biology Shanghai Institute of Biochemistry and Cell BiologyCenter for Excellence in Molecular Cell ScienceChinese Academy of SciencesUniversity of Chinese Academy of SciencesShanghai 200031China

Dear Editor,abiraterone has achieved great success in clinic by targeting cytochrome P45017A1(CYP17A)for prostate cancer therapy.1,2 However,drug resistance is inevitable and novel strategy is urgently *** previous work unveils a steroidal metabolic pathway for abiraterone in patients.3,4 Steroidogenic enzyme 3β-hydroxysteroid dehydrogenase 1(3βHSD1)catalyzes abiraterone toΔ4-abiraterone(D4A),which is further catalyzed to 5α-abiraterone(5α-Abi)by steroid-5α-reductase(SRD5A).The metabolite 5α-Abi binds to androgen receptor(AR)directly and activates AR signaling.

关键词： abiraterone CYP17 cancer

Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Oncology 2015年第4期6卷 64-72页

作者： Raji Shameem Muhammad Saad Hamid Kevin Y Xu Shenhong Wu Department of Hematology/Oncology Fox Chase Cancer Center Department of Internal Medicine Detroit Medical Center/Wayne State University Department of Medical Education Icahn School of Medicine at Mount Sinai Division of Hematology/Oncology Department of MedicineStony Brook University School of Medicine Northport VA Medical Center

AIM: To study the efficacy and safety of abiraterone in patients with and without prior ***: The databases including Pub Med and abstracts presented at the American Society of Clinical Oncology meetings up to April 2014 were systematically searched. Eligible studies included randomized controlled trials(RCTs) in which abiraterone plus prednisone was compared to placebo plus prednisone in metastatic castration-resistant prostate cancer(CRPC) patients. The summary incidence, relative risk, hazard ratio and 95%CI were calculated using random or fixed-effects models. Heterogeneity test was performed to test between-study differences in efficacy and ***: A total of two phase III RCTs were included in our analysis, with metastatic CPRC patients before(n = 1088) and after chemotherapy(n = 1195). Prior chemotherapy did not significantly alter the effect of abiraterone on overall survival(P = 0.92) and prostatespecific antigen(PSA) progression-free survival(P = 0.13), but reduced its effect on radiographic-prog-ression-free survival(P = 0.04), objective response rate(P abiraterone. There was no significant difference of cardiac disorders associated with abiraterone between the two settings(P = 0.58). CONCLUSION: Prior chemotherapy may reduce the effectiveness of abiraterone in patients with metastatic CRPC.

关键词： abiraterone Docetaxel Metastatic castration-resistant prostate cancer Chemotherapy-naïve Pre-chemotherapy Post-chemotherapy

A phase 3,double-blind,randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapynaı¨ve patients with mCRPC in China,Malaysia,Thailand and Russia

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Urology 2017年第2期4卷 75-85页

作者： Dingwei Ye Yiran Huang Fangjian Zhou Keji Xie Vsevolod Matveev Changling Li Boris Alexeev Ye Tian Mingxing Qiu Hanzhong Li Tie Zhou Peter De Porre Margaret Yu Vahid Naini Hongchuan Liang Zhuli Wu Yinghao Sun Department of Urology Fudan University Shanghai Cancer CenterShanghaiChina Department of Urology Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina Laboratory of Oncology in South China Sun Yat-sen University Cancer CenterGuangzhouGuangdongChina Guangzhou First Municipal People’s Hospital GuangzhouGuangdongChina Department of Urology Russian Academy of Medical SciencesMoscowRussia Department of Urology Cancer Institute(Hospital)Peking Union Medical College and Chinese Academy of Medical SciencesBeijingChina Department of Oncology Moscow Oncology Research InstituteMoscowRussia Department of Stomatology Beijing Friendship HospitalCapital Medical UniversityBeijingChina Department of Urology Sichuan Academy of Medical Science&Sichuan Provincial People’s HospitalChengduSichuanChina Department of Oncology Peking Union Medical College HospitalBeijingChina Department of Urology Changhai HospitalSecond Military Medical UniversityShanghaiChina Department of Oncology Janssen Research&DevelopmentBeerseBelgium Department of Medical Oncology Janssen Research&DevelopmentSan DiegoCAUSA Department of Urology Janssen Research&DevelopmentBeijingChina

Objective:This double-blind,placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate+prednisone(abiraterone)to prednisone alone in chemotherapy-naı¨ve,asymptomatic or mildly symptomatic metastatic castrationresistant prostate cancer(mCRPC)patients from China,Malaysia,Thailand and ***:Adult chemotherapy-naı¨ve patients with confirmed prostate adenocarcinoma,Eastern Cooperative Oncology Group(ECOG)performance status(PS)grade 0e1,ongoing androgen deprivation(serum testosteroneabiraterone acetate(1000 mg,QD)t prednisone(5 mg,BID)or placebo t prednisone(5 mg,BID),until disease progression,unacceptable toxicity or consent *** endpoint was improvements in time to PSA progression(TTPP).Results:Totally,313 patients were randomized(abiraterone:n Z 157;prednisone:n Z 156);and baseline characteristics were *** clinical cut-off(median follow-up time:3.9 months),80% patients received treatment(abiraterone:n Z 138,prednisone:n Z 112).Median time to PSA progression was not reached with abiraterone versus 3.8 months for prednisone,attaining 58%reduction in PSA progression risk(HR=0.418;pabirateronetreated patients had higher confirmed PSA response rate(50%vs.21%;relative odds=2.4;pabiraterone ***-treated)adverse events:bone pain(7%vs.14%),pain in extremity(6%vs.12%),arthralgia(10%vs.8%),back pain(7%vs.11%),and hypertension(15%vs.14%).Conclusion:Interim analysis confirmed favorable benefit-to-risk ratio of abiraterone in chemotherapy-naı¨ve men with mCRPC,consistent with global study,thus supporting use of abiraterone in this patient population.

关键词： abiraterone Chemotherapy-naı¨ve Metastatic castrationresistant prostate cancer Prostate specific antigen Prednisone

Early Evaluation of PSA Response in Metastatic Prostate Cancer Treated with abiraterone

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Open Journal of Urology 2021年第7期11卷 251-263页

作者： Ana Santafé-Jiménez Virginia Morillo-Macías Angel Sánchez-Iglesias Encarnación Fernández-Camacho Carlos Ferrer-Albiach Consorcio Hospitalario Provincial de Castellón Castellón de la Plana Spain

Background: According to the main prostate cancer guidelines, the response to treatment with abiraterone plus prednisone (AA+P) must be evaluated by assessing prostate-specific antigen (PSA) levels at 12 weeks. Recent studies have shown that early PSA decline, at 4 weeks, maybe a surrogate marker for survival. The objective of this work was to analyze if a decline in PSA at 4 weeks correlates with a better outcome in terms of OS (overall survival) and PFS (progression-free survival). Methods: We evaluated 168 patients (with a median age of 71 years) with prostate cancer who had started AA+P treatment between February 2012 and July 2019. Patients were divided into three different groups according to the decline of PSA (≥30%, ≥50%, and ≥90%) at 4, 8, and 12 weeks. Statistical survival analysis was performed using the Kaplan-Meier method. Results: After a follow-up of 69 months, a PSA decline ≥ 30% at 4 weeks was associated with longer median OS times (28 vs. 18 months;p = 0.027). A decline in PSA by ≥50% was also associated with increased median OS times (36 vs. 21;p = 0.003). Cox univariable analysis indicated that a decrease in PSA (both by ≥30% and ≥50) were predictive of OS at 4 weeks (PSA ≥ 30%: HR = 1.568, 95%CI [1.041, 2.360], p = 0.031;PSA ≥ 50%: HR = 1.901, 95% CI [1.222, 2.956], p = 0.004);although multivariable analysis did not confirm these results. The prior administration of chemotherapy was an independent risk factor for death (HR = 2.511;p Conclusion: A decrease in PSA by ≥30% or ≥50% at 4 weeks after starting treatment with AA+P correlated with longer PFS and OS, and provides clinically meaningful information guiding the physicians towards a personalized treatment.

关键词： Prostate Cancer abiraterone Prostate-Specific Antigen Decline Survival

Super-enhancers drive the core transcriptional regulatory circuitry to regulate abiraterone resistance in castration-resistant prostate cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Super-enhancers drive the core transcriptional regulatory ci...

abiraterone用于未化疗的转移性激素抵抗性前列腺癌(mCRPC)

2021年中国肿瘤标志物学术大会暨第十五届肿瘤标志物青年科学家论坛

作者： Jiamin Wang Xianping Shi School of Basic Medicine Guangzhou Medical University

Objective: Prostate cancer is the most common malignancy of male genitourinary system. Castration refractory prostate cancer(CRPC) is the leading cause of cancer-related death in men in the United States. Due to the relative lack of treatment options, almost all patients with CRPC eventually develop androgen treatment-resistant CRPC as the disease progresses. The potential mechanism of androgen therapy resistance to CRPC is still unknown. Therefore, it is vital to identify new carcinogenic pathways for the treatment of androgen treatment-resistant CRPC, and more efficient drugs are urgently needed because of the lack of valid chemotherapies that can provide satisfactory clinical outcomes for androgen treatment-resistant CRPC ***-enhancers(SEs) are large clusters of transcriptional enhancers, including populations of transcription factors(TFs), cofactors, chromatin regulators, and transcription apparatus occupying super-enhancers,which drive the expression of genes that define cell identity. Tumor cells assemble their own specific SEs to form a core transcriptional regulation circuits(CRCs), which significantly promotes the expression of multiple oncogenes, thereby enhances the ability of tumor cell proliferation, invasion and *** this study, by comparing the transcription profiles of super enhancers in abiraterone-resistant/sensitive CRPC cell lines, the key role of specific super enhancers in the regulation of CRCs during the development of abiraterone-resistant CRPC was explored, providing guidance for the delay of the development of abiraterone-resistant CRPC and clinical target ***: Super enhancer regulatory profiles and transcriptional expression levels of abiraterone resistant/sensitive cell lines and tumor specimens were obtained by chromatin immunoprecipitation sequencing(ChIP-seq) and RNA sequencing(RNA-seq), and transcriptional factor regulatory profiles were obtained by TF ChIP sequencing. Through "ROSE", "CRCapper" and ot

关键词： CRPC abiraterone Super enhancer Core transcriptional regulation circuits CRC

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

泌尿外科杂志（电子版） 2014年第1期6卷 58-59页

作者：陈友根

背景:醋酸阿比特龙,被美国FDA批准作为化疗后的二线治疗药物用于转移性激素抵抗性前列腺癌(mCRPC),提高了总生存率。在此评估其用于未接受过化疗患者的效果。方法:在这项双盲研究中,随机分配1088例患者接受醋酸阿比特龙(1000mg)加泼尼松... 详细信息

背景:醋酸阿比特龙,被美国FDA批准作为化疗后的二线治疗药物用于转移性激素抵抗性前列腺癌(mCRPC),提高了总生存率。在此评估其用于未接受过化疗患者的效果。方法:在这项双盲研究中,随机分配1088例患者接受醋酸阿比特龙(1000mg)加泼尼松(5mg,每日2次)或安慰剂加泼尼松。共同主要终点为影像学无进展生存期和总生存期。结果:预期死亡人数达到43%后。

关键词： abiraterone mCRPC 抵抗性无进展生存期二线治疗药物双盲研究影像学安慰剂雌二醇氮芥中位缓解时间